EUVIMEDEUVIMED entdecken
Crossref

A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis

Yimin Dong, Honglei Kang, Renpeng Peng, Zheming Liu, Fuben Liao, Shi-An Hu, Weizhong Ding, Pengju Wang, Pengchao Yang, Meipeng Zhu, Sibo Wang, Minglong Wu und 4 weitere

Cell Metabolism · 2024-08 · 36 (8) · 1679-1695.e6

DOI: 10.1016/j.cmet.2024.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2024-08. Verfasst von Yimin Dong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Cell Differentiation, Osteoclasts, Iron. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Key Research and Development Program of Hunan Province of China, Huazhong Agricultural University, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activating Nrf2 by small molecules is a promising strategy to treat postmenopausal osteoporosis. However, there is currently no Nrf2 activator approved for treating chronic diseases, and the downstream mechanism underlying the regulation of Nrf2 on osteoclast differentiation remains unclear. Here, we found that bitopertin, a clinical-stage glycine uptake inhibitor, suppresses osteoclast differentiation and ameliorates ovariectomy-induced bone loss by activating Nrf2. Mechanistically, bitopertin interacts with the Keap1 Kelch domain and decreases Keap1-Nrf2 binding, leading to reduced Nrf2 ubiquitination and degradation. Bitopertin is associated with less adverse events than clinically approved Nrf2 activators in both mice and human subjects. Furthermore, Nrf2 transcriptionally activates ferroportin-coding gene Slc40a1 to reduce intracellular iron levels in osteoclasts. Loss of Nrf2 or iron supplementation upregulates ornithine-metabolizing enzyme Odc1, which decreases ornithine levels and thereby promotes osteoclast differentiation. Collectively, our findings identify a novel clinical-stage Nrf2 activator and propose a novel Nrf2-iron-ornithine metabolic axis in osteoclasts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Cell DifferentiationOsteoclastsIronMice, Inbred C57BLAnimalsMiceHumansKelch-Like ECH-Associated Protein 1FemaleCation Transport ProteinsFerroportin

Stichwörter der Autor:innen

NRF2Odc1Slc40a1bitopertinironornithineosteoclastosteoporosis

Substanzen

NF-E2-Related Factor 2IronKelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseFerroportinCation Transport Proteins

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
  • Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: lifengmd@hust.edu.cn.
  • Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: kehansong@tjh.tjmu.edu.cn.

Förderung

  • Key Research and Development Program of Hunan Province of China
  • Huazhong Agricultural University
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Huazhong University of Science and Technology

Zitieren

APA

Dong, Y., Kang, H., Peng, R., Liu, Z., Liao, F., Hu, S. A., Ding, W., Wang, P., Yang, P., Zhu, M., Wang, S., Wu, M., Ye, D., Gan, X., Li, F., & Song, K. (2024). A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis. Cell Metabolism, 36(8), 1679-1695.e6. https://doi.org/10.1016/j.cmet.2024.03.005

Vancouver

Dong Y, Kang H, Peng R, Liu Z, Liao F, Hu SA, et al. A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis. Cell Metabolism. 2024;36(8):1679-1695.e6. doi:10.1016/j.cmet.2024.03.005

BibTeX
@article{Dong2024,
  author = {Dong, Yimin and Kang, Honglei and Peng, Renpeng and Liu, Zheming and Liao, Fuben and Hu, Shi-An and Ding, Weizhong and Wang, Pengju and Yang, Pengchao and Zhu, Meipeng and Wang, Sibo and Wu, Minglong and Ye, Dawei and Gan, Xin and Li, Feng and Song, Kehan},
  title = {A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis},
  journal = {Cell Metabolism},
  year = {2024},
  volume = {36},
  number = {8},
  pages = {1679--1695.e6},
  doi = {10.1016/j.cmet.2024.03.005}
}
Kostenlos starten →